{"id":"pik3ca","name":"PIK3CA / PI3K-alpha","symbol":"PIK3CA","route":"/targets/pik3ca/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8975","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000121879","uniprot":"https://www.uniprot.org/uniprotkb/P42336/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P42336","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL4005","open-targets":"https://platform.opentargets.org/target/ENSG00000121879","civic":"https://civicdb.org/genes/5290/summary","oncokb":"https://www.oncokb.org/gene/PIK3CA","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PIK3CA","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=PIK3CA","depmap":"https://depmap.org/portal/gene/PIK3CA?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000121879-PIK3CA","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/5290","omim":"https://www.omim.org/entry/171834"}],"products":[{"id":"alpelisib","name":"Alpelisib","status":"approved","modality":"Small-molecule PI3Kα inhibitor","route":"/drugs/alpelisib/"},{"id":"capivasertib","name":"Capivasertib","status":"approved","modality":"Small-molecule AKT inhibitor","route":"/drugs/capivasertib/"},{"id":"copanlisib","name":"Copanlisib","status":"withdrawn","modality":"Intravenous pan-class I PI3K inhibitor (α/δ predominant)","route":"/drugs/copanlisib/"},{"id":"duvelisib","name":"Duvelisib","status":"approved","modality":"Small-molecule PI3Kδ/γ inhibitor","route":"/drugs/duvelisib/"},{"id":"everolimus","name":"Everolimus","status":"approved","modality":"Small-molecule mTOR inhibitor","route":"/drugs/everolimus/"},{"id":"gedatolisib","name":"Gedatolisib","status":"approved","modality":"Small-molecule pan-PI3K/mTOR inhibitor","route":"/drugs/gedatolisib/"},{"id":"idelalisib","name":"Idelalisib","status":"approved","modality":"Small-molecule PI3Kδ inhibitor","route":"/drugs/idelalisib/"},{"id":"inavolisib","name":"Inavolisib","status":"approved","modality":"Small-molecule PI3Kα inhibitor and degrader","route":"/drugs/inavolisib/"},{"id":"serabelisib","name":"Serabelisib","status":"phase-2","modality":"small molecule","route":"/drugs/serabelisib/"},{"id":"tersolisib","name":"Tersolisib","status":"phase-3","modality":"small molecule","route":"/drugs/tersolisib/"},{"id":"therascreen-cdx","name":"therascreen companion diagnostic kits (KRAS, EGFR, PIK3CA, FGFR, BRAF)","status":"approved","modality":"Real-time PCR companion diagnostic test family","route":"/drugs/therascreen-cdx/"},{"id":"umbralisib","name":"Umbralisib","status":"withdrawn","modality":"Oral PI3Kδ / CK1ε inhibitor","route":"/drugs/umbralisib/"},{"id":"zovegalisib","name":"Zovegalisib","status":"phase-3","modality":"small molecule","route":"/drugs/zovegalisib/"}],"trials":[{"id":"nct03997123","name":"Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC","nct":"NCT03997123","phase":"3","status":"active"},{"id":"alascca","name":"ALASCCA","nct":"NCT02647099","phase":"3","status":"positive"},{"id":"capitello-281","name":"CAPItello-281","nct":"NCT04493853","phase":"3","status":"positive"},{"id":"compete","name":"COMPETE","nct":"NCT03049189","phase":"3","status":"positive"},{"id":"evera","name":"evERA","nct":"NCT05306340","phase":"3","status":"positive"},{"id":"ipatunity130","name":"IPATunity130","nct":"NCT03337724","phase":"3","status":"negative"},{"id":"nct02970318","name":"A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL","nct":"NCT02970318","phase":"3","status":"active"},{"id":"litespark-005","name":"LITESPARK-005","nct":"NCT04195750","phase":"3","status":"positive"},{"id":"capitello-291","name":"CAPItello-291","nct":"NCT04305496","phase":"3","status":"positive"},{"id":"clear","name":"CLEAR (KEYNOTE-581)","nct":"NCT02811861","phase":"3","status":"positive"},{"id":"solar-1","name":"SOLAR-1","nct":"NCT02437318","phase":"3","status":"positive"},{"id":"checkmate-025","name":"CheckMate 025","nct":"NCT01668784","phase":"3","status":"positive"},{"id":"bolero-2","name":"BOLERO-2","nct":"NCT00863655","phase":"3","status":"positive"},{"id":"radiant-3-4","name":"RADIANT-3 and RADIANT-4","nct":"NCT00510068","phase":"3","status":"positive"},{"id":"nct06764186","name":"A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain","nct":"NCT06764186","phase":"3","status":"active"},{"id":"nct06790693","name":"A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer","nct":"NCT06790693","phase":"3","status":"recruiting"},{"id":"nct05646862","name":"A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy","nct":"NCT05646862","phase":"3","status":"recruiting"},{"id":"nct06522737","name":"A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype","nct":"NCT06522737","phase":"3","status":"recruiting"},{"id":"nct06846671","name":"A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors","nct":"NCT06846671","phase":"3","status":"recruiting"},{"id":"pik3ca-2","name":"A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)","nct":"NCT07174336","phase":"3","status":"recruiting"},{"id":"nct05894239","name":"A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer","nct":"NCT05894239","phase":"3","status":"recruiting"},{"id":"nct04862663","name":"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)","nct":"NCT04862663","phase":"3","status":"active"},{"id":"nct06635447","name":"Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients","nct":"NCT06635447","phase":"3","status":"active"},{"id":"nct05918302","name":"Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.","nct":"NCT05918302","phase":"3","status":"recruiting"},{"id":"nct05501886","name":"Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)","nct":"NCT05501886","phase":"3","status":"active"},{"id":"nct04919226","name":"Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE","nct":"NCT04919226","phase":"3","status":"active"},{"id":"nct06757634","name":"Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)","nct":"NCT06757634","phase":"3","status":"recruiting"},{"id":"nct06982521","name":"Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer","nct":"NCT06982521","phase":"3","status":"recruiting"},{"id":"nct04208178","name":"Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation","nct":"NCT04208178","phase":"3","status":"active"},{"id":"nct05348577","name":"Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)","nct":"NCT05348577","phase":"3","status":"active"},{"id":"nct05038735","name":"Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.","nct":"NCT05038735","phase":"3","status":"active"},{"id":"nct03801525","name":"Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)","nct":"NCT03801525","phase":"2/3"},{"id":"inavo120","name":"INAVO120","nct":"NCT04191499","phase":"2/3","status":"positive"},{"id":"nct05948943","name":"Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.","nct":"NCT05948943","phase":"2/3","status":"recruiting"},{"id":"nct07165886","name":"Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors","nct":"NCT07165886","phase":"2/3","status":"recruiting"},{"id":"nct02793583","name":"Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma","nct":"NCT02793583","phase":"2/3"},{"id":"nci-match","name":"NCI-MATCH (EAY131)","nct":"NCT02465060","phase":"platform","status":"active"},{"id":"nct04624633","name":"Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL","nct":"NCT04624633","phase":"2","status":"active"},{"id":"national-lung-matrix-trial","name":"National Lung Matrix Trial","nct":"NCT02664935","phase":"2","status":"completed"},{"id":"pakt","name":"PAKT","nct":"NCT02423603","phase":"2","status":"positive"},{"id":"plasmamatch","name":"plasmaMATCH","nct":"NCT03182634","phase":"2","status":"completed"},{"id":"lotus","name":"LOTUS","nct":"NCT02162719","phase":"2","status":"positive"},{"id":"nct07405801","name":"A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer","nct":"NCT07405801","phase":"2","status":"recruiting"},{"id":"nct07441512","name":"A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer","nct":"NCT07441512","phase":"2","status":"planned"},{"id":"nct07287150","name":"A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer","nct":"NCT07287150","phase":"2","status":"recruiting"},{"id":"nct07054190","name":"A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer","nct":"NCT07054190","phase":"2","status":"recruiting"},{"id":"nct06301386","name":"Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients","nct":"NCT06301386","phase":"2","status":"planned"},{"id":"nct07340541","name":"Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies","nct":"NCT07340541","phase":"2","status":"recruiting"},{"id":"nct05749588","name":"FUSCC Refractory TNBC Platform Study (FUTURE2.0)","nct":"NCT05749588","phase":"2","status":"recruiting"},{"id":"nct06463028","name":"Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial ","nct":"NCT06463028","phase":"2","status":"recruiting"},{"id":"nct04524000","name":"Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer","nct":"NCT04524000","phase":"2","status":"active"},{"id":"nct04544189","name":"Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer","nct":"NCT04544189","phase":"2","status":"active"},{"id":"nct06428396","name":"Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)","nct":"NCT06428396","phase":"2","status":"active"},{"id":"nct05725200","name":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer","nct":"NCT05725200","phase":"2","status":"recruiting"},{"id":"nct07368998","name":"To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer","nct":"NCT07368998","phase":"2","status":"recruiting"},{"id":"nct04589845","name":"Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study","nct":"NCT04589845","phase":"2","status":"active"},{"id":"nct03742102","name":"A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer","nct":"NCT03742102","phase":"1/2","status":"active"},{"id":"nct07002177","name":"A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC","nct":"NCT07002177","phase":"1/2","status":"recruiting"},{"id":"nct04802759","name":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer","nct":"NCT04802759","phase":"1/2","status":"recruiting"},{"id":"nct05230810","name":"Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.","nct":"NCT05230810","phase":"1/2","status":"active"},{"id":"nct07617805","name":"EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC","nct":"NCT07617805","phase":"1/2","status":"recruiting"},{"id":"nct06190899","name":"Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer","nct":"NCT06190899","phase":"1/2","status":"recruiting"},{"id":"nct05563220","name":"Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer","nct":"NCT05563220","phase":"1/2","status":"active"},{"id":"nct05573126","name":"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer","nct":"NCT05573126","phase":"1/2","status":"recruiting"},{"id":"nct07558733","name":"Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer","nct":"NCT07558733","phase":"1/2","status":"recruiting"},{"id":"nct07287917","name":"Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors","nct":"NCT07287917","phase":"1/2","status":"recruiting"}],"pathways":["bcr-abl1-signalling","breast-cancer-signalling","chemical-carcinogenesis-receptor-activation","immune-desert-exclusion","colorectal-cancer-signalling","endometrial-cancer-signalling","fgfr-signalling","gastric-cancer-signalling","glioma-signalling","pancreatic-cancer-signalling","pi3k-akt-mtor","proteoglycans-in-cancer","rtk-activation","resistance-routes-map"],"companies":["astrazeneca","bayer","bridgebio-oncology-therapeutics","celcuity","cogent-biosciences","eli-lilly","gilead","infinity-pharmaceuticals","novartis","qiagen","recursion","relay-therapeutics","roche-genentech","scorpion-therapeutics","takeda","tg-therapeutics"],"keyPapers":["paper-zhu-population-specific-immunogenomics-gallbladder-cancer-mod-pathol-2025","paper-giraldo-gallbladder-msk-impact-ccr-2022","paper-schmid-pakt-capivasertib-tnbc-jco-2020","paper-marcoux-egfr-small-cell-transformation-outcomes-jco-2019","paper-jiang-fuscc-tnbc-landscape-cancer-cell-2019","paper-chung-comprehensive-genomic-profiling-prostate-jco-po-2019","paper-narayan-gallbladder-regional-mutations-cancer-2019","paper-loree-tumour-location-continuum-colorectal-ccr-2018","paper-yaeger-metastatic-colorectal-genomic-landscape-cancer-cell-2018","paper-bareche-tnbc-multiomic-heterogeneity-ann-oncol-2018","paper-huo-tcga-ancestry-breast-jama-oncol-2017","paper-robinson-integrative-clinical-genomics-advanced-prostate-cell-2015","paper-tcga-molecular-taxonomy-primary-prostate-cell-2015","paper-kris-lung-cancer-mutation-consortium-jama-2014","paper-vogelstein-cancer-genome-landscapes-science-2013","paper-tcga-lung-squamous-nature-2012","paper-tcga-colorectal-comprehensive-characterization-nature-2012","paper-tcga-breast-molecular-portraits-nature-2012","paper-shah-tnbc-clonal-evolution-nature-2012","paper-carver-pi3k-ar-reciprocal-feedback-prostate-cancer-cell-2011"],"hotspots":[{"label":"E542K / E545K","position":545,"kind":"activating","frequency":"Helical hotspots; with H1047R they account for about 80% of PIK3CA mutations","drugs":["alpelisib","inavolisib","capivasertib"]},{"label":"H1047R / H1047L","position":1047,"kind":"activating","frequency":"The single most common PIK3CA allele","drugs":["alpelisib","inavolisib","capivasertib"]}],"openQuestions":[],"assays":[{"id":"foundationone-cdx-panel","name":"FoundationOne CDx","cutoff":"Per companion claim: EGFR, ALK, BRAF V600, ERBB2 amplification, KRAS wild-type, BRCA1/2 and HRR genes, PIK3CA, MET exon 14, RET, FGFR2 fusions, IDH1, NTRK fusions; MSI-high; TMB at least 10 mutations per megabase"},{"id":"foundationone-liquid-cdx","name":"FoundationOne Liquid CDx","cutoff":"Per companion claim: EGFR (osimertinib, erlotinib, gefitinib), ALK (alectinib), BRCA1/2 and ATM (olaparib, rucaparib), PIK3CA (alpelisib), FGFR3 (erdafitinib), NTRK and RET; negative plasma results reflex to tissue"},{"id":"pik3ca-therascreen","name":"therascreen PIK3CA RGQ PCR Kit","cutoff":"Mutation detected (alpelisib plus fulvestrant); plasma negative reflexes to tissue"}],"resistance":[{"class":"cdk46-endocrine","mechanism":"PI3K/AKT/mTOR activation","category":"bypass"},{"class":"ar-pathway","mechanism":"AR amplification and ligand-binding-domain mutations","category":"on-target"},{"class":"ar-pathway","mechanism":"AR splice variants (AR-V7)","category":"on-target"},{"class":"ar-pathway","mechanism":"Lineage plasticity to neuroendocrine prostate cancer","category":"lineage"},{"class":"ar-pathway","mechanism":"PI3K/AKT activation via PTEN loss","category":"bypass"},{"class":"ar-pathway","mechanism":"Glucocorticoid receptor substitution","category":"bypass"}],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}